Zachary Harris, MD
Assistant ProfessorCards
About
Research
Publications
2026
When a Pandemic Challenges the Art of Medicine
Harris Z. When a Pandemic Challenges the Art of Medicine. Southern Medical Journal 2026, 119: 155-156. DOI: 10.14423/smj.0000000000001940.Peer-Reviewed Original ResearchEpidermal growth factor receptor regulates Beclin-1 in hyperoxic acute lung injury
Harris Z, Korde A, Khoury J, Manning E, Stanley G, Shin Y, Mitchell K, von der Schulenburg A, Sun Y, Hu B, Shin H, Joerns J, Clark B, Placek L, Unutmaz D, Moldobaeva A, Sharma L, Sauler M, Rajagopalan G, Zhang X, Wang H, Ghaedi M, Kang M, Koff J. Epidermal growth factor receptor regulates Beclin-1 in hyperoxic acute lung injury. BMJ Open Respiratory Research 2026, 13: e003323. PMID: 41592865, PMCID: PMC12853440, DOI: 10.1136/bmjresp-2025-003323.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorAcute lung injuryHyperoxic ALIHyperoxic acute lung injuryGrowth factor receptorIn vivo effectsLung injuryOxidant-mediated acute lung injuryFactor receptorIntensive care unit mortalityExposure to high oxygenAlveolar type II cellsDelivery of supplemental oxygenPulmonary cell deathLife-saving therapyPluripotent stem cellsType II cellsNormoxia controlSupplemental oxygenUnit mortalityAlveolar epitheliumBeclin-1Cell death pathwaysStem cellsTherapeutic potential
2025
Epidermal Growth Factor Receptor Regulates Beclin-1 and Autophagy in Hyperoxic Acute Lung Injury
Harris Z, Korde A, Khoury J, Manning E, Stanley G, Sun Y, Hu B, Shin H, Joerns J, Clark B, Mitchell K, Placek L, Unutmaz D, Moldobaeva A, Sharma L, Sauler M, Rajagopalan G, Zhang X, Wang H, Ghaedi M, Kang M, Koff J. Epidermal Growth Factor Receptor Regulates Beclin-1 and Autophagy in Hyperoxic Acute Lung Injury. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a2472-a2472. DOI: 10.1164/ajrccm.2025.211.abstracts.a2472.Peer-Reviewed Original ResearchPersonalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis
Chan B, Stanley G, Kortright K, Vill A, Modak M, Ott I, Sun Y, Würstle S, Grun C, Kazmierczak B, Rajagopalan G, Harris Z, Britto C, Stewart J, Talwalkar J, Appell C, Chaudary N, Jagpal S, Jain R, Kanu A, Quon B, Reynolds J, Teneback C, Mai Q, Shabanova V, Turner P, Koff J. Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis. Nature Medicine 2025, 31: 1494-1501. PMID: 40301561, PMCID: PMC12092284, DOI: 10.1038/s41591-025-03678-8.Peer-Reviewed Original ResearchConceptsPhage therapyCystic fibrosisEvidence of trade-offsTreated with phagesEvolutionary trade-offClinical impact of antimicrobial resistanceMultidrug-resistant Pseudomonas aeruginosaBacterial virulenceAntimicrobial resistance crisisLytic virusesDecrease antibiotic resistanceSputum microbiomePhageBacteriophage therapyImpact of antimicrobial resistanceAntibiotic resistanceResistance crisisStandard antibioticsAntimicrobial resistanceSputum densityMultidrug resistancePulmonary infectionCompassionate basisClinical courseMedian age
2024
Cystic Fibrosis Bacteriophage Study at Yale (CYPHY)
Stanley G, Cochrane C, Chan B, Kortright K, Rahman B, Lee A, Vill A, Sun Y, Stewart J, Britto-Leon C, Harris Z, Talwalker J, Shabanova V, Turner P, Koff J. Cystic Fibrosis Bacteriophage Study at Yale (CYPHY). American Journal Of Respiratory And Critical Care Medicine 2024, 209: a6808-a6808. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6808.Peer-Reviewed Original ResearchEpidermal Growth Factor Receptor Regulates Beclin-1 in Hyperoxia-Induced Lung Injury
Harris Z, Sun Y, Korde A, Hu B, Sharma L, Manning E, Joerns J, Clark B, Stanley G, Shin H, Placek L, Unutmaz D, Chun H, Sauler M, Rajagopalan G, Zhang X, Wang H, Kang M, Koff J. Epidermal Growth Factor Receptor Regulates Beclin-1 in Hyperoxia-Induced Lung Injury. American Journal Of Respiratory And Critical Care Medicine 2024, 209: a6841-a6841. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6841.Peer-Reviewed Original Research
2023
41 CYstic Fibrosis bacterioPHage study at Yale (CYPHY)
Chan B, Kortright K, Stanley G, Cochrane C, Lee A, Vill A, Sun Y, Stewart J, Britto-Leon C, Harris Z, Talkwalkar J, Shabanova V, Turner P, Koff J. 41 CYstic Fibrosis bacterioPHage study at Yale (CYPHY). Journal Of Cystic Fibrosis 2023, 22: s22. DOI: 10.1016/s1569-1993(23)00976-1.Peer-Reviewed Original ResearchProtracted Pulmonary Inflammation in IFN-gamma Deficient Mice Recovering from Cytokine Release Syndrome
Rajagopalan G, Sun Y, Hu B, Harris Z, Stanely G, Koff J. Protracted Pulmonary Inflammation in IFN-gamma Deficient Mice Recovering from Cytokine Release Syndrome. American Journal Of Respiratory And Critical Care Medicine 2023, 207: a1386-a1386. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a1386.Peer-Reviewed Original ResearchA Novel Zinc (II) Porphyrin Is Synergistic with PEV2 Bacteriophage against Pseudomonas aeruginosa Infections
Geyer J, Krupa K, Harris Z, Sun Y, Sharma L, Würstle S, Hu B, Stanley G, Rajagopalan G, Pellot E, Koff J, Robinson J. A Novel Zinc (II) Porphyrin Is Synergistic with PEV2 Bacteriophage against Pseudomonas aeruginosa Infections. Antibiotics 2023, 12: 735. PMID: 37107097, PMCID: PMC10135120, DOI: 10.3390/antibiotics12040735.Peer-Reviewed Original ResearchMinimum inhibitory concentrationMinimum bactericidal concentrationCystic fibrosisAntiviral activityPseudomonas aeruginosa infectionLife-threatening infectionsAntibiotic-resistant infectionsDose-dependent responsePulmonary infectionPotent bactericidal activityAeruginosa infectionMouse lungPsA populationImmune systemVivo modelLung cellsPSA cellsHealth concernNovel therapeuticsInfectionLung modelH441 cellsOpportunistic bacterial pathogenSignificant decreaseInhibitory concentrationIFN-γ Is Protective in Cytokine Release Syndrome-associated Extrapulmonary Acute Lung Injury.
Sun Y, Hu B, Stanley G, Harris ZM, Gautam S, Homer R, Koff JL, Rajagopalan G. IFN-γ Is Protective in Cytokine Release Syndrome-associated Extrapulmonary Acute Lung Injury. American Journal Of Respiratory Cell And Molecular Biology 2023, 68: 75-89. PMID: 36125351, PMCID: PMC9817908, DOI: 10.1165/rcmb.2022-0117oc.Peer-Reviewed Original ResearchConceptsCytokine release syndromeAcute lung injuryExtrapulmonary acute lung injuryIFN-γ KO miceIL-17ALung injuryKO miceStaphylococcal enterotoxin BRelease syndromeIL-17A KO miceSevere acute lung injuryAcute respiratory distress syndromeSystemic T cell activationEnterotoxin BAdaptive T lymphocytesDR3 transgenic miceNeutralization of IFNRespiratory distress syndromeHuman leukocyte antigenRole of IFNT cell cytokinesJanus kinase inhibitorS100A8/A9T cell activationALI parameters
Academic Achievements & Community Involvement
Clinical Care
Overview
Zachary Harris, MD, is a pulmonary, critical care, and sleep medicine specialist who says he grew up knowing he wanted to become a physician and a researcher.
“I went into medical school with a lot of interests and it was like the pulmonary and critical care field chose me,” Dr. Harris says. “I enjoyed critical care medicine and at the same time, liked treating patients in the clinic and on the general medicine floors of the hospital.”
Whether it’s taking care of patients in the intensive care unit (ICU) or in an office setting, Dr. Harris says he appreciates the diversity of his work. “I see a wide spectrum of disease acuity and get to watch the different spheres of medicine intersect,” he says. “Taking care of people is the most rewarding aspect of being a physician. When we see patients in the ICU and they are really sick, it’s our job to not only treat them, but to help families through difficult times. We want to be clear in the trajectory of how things are going—to provide reassurance, information, and compassion.”
In addition to general pulmonary and critical care, Dr. Harris sees patients in the Post-COVID-19 Recovery Program and in the Adult Cystic Fibrosis Program. “It has been a great opportunity to get to know patients with cystic fibrosis and help them live long, rewarding lives,” he says. “Cystic fibrosis has undergone a revolution, with new therapies that help reduce symptoms and improve quality of life.”
An active researcher, Dr. Harris is exploring novel antibiotics to treat cystic fibrosis. He is also interested in acute lung injury, which includes diseases such as acute respiratory distress syndrome (ARDS). “My research deals with understanding the mechanisms of cellular injury and cell death in ARDS, which is directly applicable to my medical practice,” he explains.
With an undergraduate degree in visual and environmental studies, Dr. Harris says he applies his background as a painter to his research. “In the laboratory, I’m studying cell and lung biology and I can use my creative skills to further my understanding of the pathogenesis of lung diseases and how they occur, as well as use novel and inventive ways to treat these diseases and improve patients’ lives,” he says.
Dr. Harris is also a physician for theConnecticut Air National Guard.
Clinical Specialties
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.